Phillip Kallen, MD
Rheumatology · Delray Beach, FLNPI 1871694505
Payments from drug & device makers
Across 296 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- E.r. Squibb & Sons, L.L.C.$751
- Novartis$627
- Amgen$566
- GSK$479
- Johnson & Johnson$384
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,876100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $1,343 |
| E.r. Squibb & Sons, L.L.C. | 40 | $751 |
| Novartis | 45 | $627 |
| Amgen(2 entities) | 28 | $566 |
| GSK | 25 | $479 |
| Johnson & Johnson(2 entities) | 20 | $384 |
| UCB, Inc. | 14 | $319 |
| Pfizer | 16 | $282 |
| Mallinckrodt Hospital Products Inc. | 6 | $197 |
| Boehringer Ingelheim | 7 | $162 |
| AstraZeneca(2 entities) | 7 | $132 |
| Genentech USA, Inc. | 6 | $122 |
| Alvogen Inc | 3 | $68 |
| Radius Health, Inc. | 3 | $62 |
| Actelion Pharmaceuticals US, Inc. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Sanofi | 2 | $36 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Sobi, Inc | 2 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Aurinia Pharma U.S., Inc. | 2 | $28 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Gilead | 1 | $14 |
How this compares
$5,876 in reported general payments places this provider in the 40th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 13 | $72,045 |
| Duloxetine Hcl | 42 | $1,993 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $1,835 |
| Celecoxib | 45 | $1,806 |
| Oxycodone Hcl | 64 | $1,670 |
| MethotrexateMethotrexate Sodium | 51 | $1,562 |
| Pregabalin | 20 | $1,329 |
| Prednisone | 71 | $1,132 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 41 | $712 |
| Hydroxychloroquine Sulfate | 19 | $591 |
| Gabapentin | 41 | $520 |
| Escitalopram Oxalate | 14 | $385 |
| Methylprednisolone | 41 | $372 |
| Tramadol Hcl | 32 | $248 |
| Alprazolam | 14 | $221 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Delray Beach
- Shawn BacaDelray Beach$1.3M
- Martha Hernandez IllasFort Lauderdale$25M
- Carlos SesinMiami Beach$19M
- Guillermo ValenzuelaPlantation$14.2M
- Marimer Rensoli VelazquezMiami$12.2M
- Robert LevinClearwater$11M
- Jigar ShahMargate$5.6M
- Michael BubbGainesville$3.3M
- Vipul JoshiBrandon$3.1M
- Alvin WellsDestin$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.